Briefcases -- Drugs -- FARXIGA (dapagliflozin) and XIGDUO XR (dapagliflozin/metformin HCI extended-release) MDL 2776 USDC SD New York

FARXIGA (dapagliflozin) and XIGDUO XR (dapagliflozin/metformin HCI extended-release) MDL 2776 USDC SD New York

Case Files
News
Committees
Request a Document
Request
Search Within Briefcase

Folders

  1. JPML Initial Transfer and Consolidation Order
  2. Initial Case Filing Templates
    1. Master Long Form and Short Form Complaints
    2. Plaintiff Fact Sheet(s)
  3. Court Orders
    1. Pretrial Orders (PTOs)
    2. Case Management Orders (CMOs)
  4. Case Pleadings
  5. Bellwether Cases
  6. Evidentiary and Research Documents
    1. Media References
    2. FDA Regulatory Materials
  7. Transcripts

Quick Access

  1. FARXIGA and XIGDUO XR MDL 2776 JPML Transfer and Consolidation Order (April 6, 2017)
  2. FARXIGA (dapagliflozin) MDL 2776 Reuters Article re Declare Clinical Trial (November 10, 2018)
  3. FARXIGA (dapagliflozin) MDL 2776 Order No. 1 Case Protocols (May 4, 2017)
  4. FARXIGA MDL 2776 FDA Approved Drug Products List (February 12, 2016)
  5. XIGDUO XR MDL 2776 FDA Letter re: New Warnings (December 4, 2015)
  6. XIGDUO XR Updated FDA Label with New Warnings and Precautions (December 2015)
  7. XIGDUO XR FDA Label with No DKA Warning (December 4, 2015)
  8. FARXIGA MDL 2776 FDA Increased Warnings and Label Revisions Letter (December 4, 2015)